Investigating the Optimal Use of Novel Immunotherapies for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Program Description

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma that accounts for 25% to 45% of new lymphoma cases annually, with 30% to 40% of patients having disease that is relapsed or refractory (R/R). R-CHOP, consisting of rituximab, an anti-CD20 antibody, along with cyclophosphamide, doxorubicin, prednisone, and vincristine, has become the standard treatment regimen due to overall improvement of outcomes. Alternative treatments, such as salvage chemotherapy followed by high-dose chemotherapy and autologous stem-cell transplantation, result in many patients experiencing relapsed disease. New and emerging therapies, including chimeric antigen receptor T-cell therapies, antibody-drug conjugates, and bispecific antibodies, have shown promise in improving patient outcomes. Pharmacists must consider various aspects of new therapies for R/R DLBCL when determining how to implement these strategies into existing clinical pathways. Pharmacists will be able to use the data presented in clinical practice as they help patients navigate traditional and emerging new therapies in the treatment of R/R DLBCL.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: November 8, 2022
Expiration date: November 8, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the data investigating new and emerging novel immunotherapies in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
• Apply emerging clinical data of novel immunotherapies into treatment pathways for relapsed/refractory DLBCL
• Differentiate roles of oncology care providers in overcoming various challenges to the use of novel immunotherapies in the treatment of DLBCL
• Identify the unique role of oncology pharmacists in overcoming various challenges to the use of novel immunotherapies in the treatment of DLBCL

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-552-H01-P. The activity is available for CE credit through November 8, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Karen M. Fancher, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Merck & Co., G1 Therapeutics, BTG International, AstraZeneca LLC

Speakers Bureau: G1 Therapeutics

Victoria Nachar, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Evelina Kolychev, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms